Artiva Biotherapeutics, Inc.
$13.39
▼
-0.15%
2026-04-21 05:24:00
www.artivabio.com
NGM: ARTV
Explore Artiva Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$310.19 M
Current Price
$13.39
52W High / Low
$13.2 / $1.47
Stock P/E
—
Book Value
$4.53
Dividend Yield
—
ROCE
-76.21%
ROE
-56.55%
Face Value
—
EPS
$-3.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
—
Debt / Equity
9.95
Current Ratio
8.61
Quick Ratio
8.61
Forward P/E
-2.75
Price / Sales
—
Enterprise Value
$71.25 M
EV / EBITDA
-0.82
EV / Revenue
—
Rating
None
Target Price
$17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 2. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 3. | CAMP4 THERAPEUTICS CORPORATION | $4.51 | — | $233.12 M | — | -50.89% | -1.45% | $7.75 / $1.3 | $0.92 |
| 4. | Fennec Pharmaceuticals Inc. | $6.73 | — | $232.02 M | — | -10.57% | -65.82% | $9.92 / $5.02 | $1.04 |
| 5. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 6. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 7. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -21.93 M | -22.9 M | -22.81 M | -22.17 M | -18.27 M | — |
| Net Profit | -20.77 M | -21.53 M | -21.25 M | -20.31 M | -19.91 M | — |
| EPS in Rs | -0.84 | -0.87 | -0.86 | -0.82 | -0.81 | -0.92 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0.25 M | 33.49 M | 4.93 M |
| Operating Profit | -89.81 M | -67.28 M | -30.67 M | -59.83 M |
| Net Profit | -83.86 M | -58.18 M | -32.77 M | -60.98 M |
| EPS in Rs | -3.39 | -2.35 | -1.33 | -2.47 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 130.94 M | 209.58 M | 105.11 M | 133.05 M |
| Total Liabilities | 20.97 M | 22.94 M | 267.13 M | 273.75 M |
| Equity | 109.97 M | 186.64 M | -162.01 M | -140.7 M |
| Current Assets | 112.67 M | 188.63 M | 79.82 M | 104.67 M |
| Current Liabilities | 13.09 M | 12.25 M | 12.23 M | 25.62 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -76.75 M | -55.03 M | -47.43 M | -50.83 M |
| Investing CF | 63.41 M | -120.46 M | -25.98 M | -6.3 M |
| Financing CF | 0.01 M | 162.23 M | 24.39 M | -1.26 M |
| Free CF | -79.34 M | -55.67 M | -50.69 M | -57.13 M |
| Capex | -2.59 M | -0.64 M | -3.26 M | -6.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -99.25% | 579.21% | — | — |
| Earnings Growth % | -77.56% | 46.26% | — | — |
| Profit Margin % | -23178.88% | -97.83% | -1236.58% | — |
| Operating Margin % | -26805.58% | -91.58% | -1213.32% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -25837.05% | -84.81% | -1189.84% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.